Annual CFO
$184.15 M
+$254.39 M+362.19%
December 31, 2024
Summary
- As of March 12, 2025, PTGX annual cash flow from operations is $184.15 million, with the most recent change of +$254.39 million (+362.19%) on December 31, 2024.
- During the last 3 years, PTGX annual CFO has risen by +$292.02 million (+270.72%).
- PTGX annual CFO is now at all-time high.
Performance
PTGX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$29.18 M
-$1.31 M-4.72%
December 31, 2024
Summary
- As of March 12, 2025, PTGX quarterly cash flow from operations is -$29.18 million, with the most recent change of -$1.31 million (-4.72%) on December 31, 2024.
- Over the past year, PTGX quarterly CFO has dropped by -$1.31 million (-4.72%).
- PTGX quarterly CFO is now -110.86% below its all-time high of $268.62 million, reached on June 30, 2024.
Performance
PTGX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
$184.15 M
-$46.14 M-20.03%
December 31, 2024
Summary
- As of March 12, 2025, PTGX TTM cash flow from operations is $184.15 million, with the most recent change of -$46.14 million (-20.03%) on December 31, 2024.
- Over the past year, PTGX TTM CFO has dropped by -$46.14 million (-20.03%).
- PTGX TTM CFO is now -20.47% below its all-time high of $231.54 million, reached on June 30, 2024.
Performance
PTGX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
PTGX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +362.2% | -4.7% | -20.0% |
| 3 y3 years | +270.7% | -4.7% | -20.0% |
| 5 y5 years | +543.5% | -4.7% | -20.0% |
PTGX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +270.3% | -110.9% | +22.5% | -20.5% | +255.0% |
| 5 y | 5-year | at high | +270.3% | -110.9% | +22.5% | -20.5% | +255.0% |
| alltime | all time | at high | +270.3% | -110.9% | +22.5% | -20.5% | +255.0% |
Protagonist Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $184.15 M(-362.2%) | -$29.18 M(+4.7%) | $184.15 M(-20.0%) |
| Sep 2024 | - | -$27.86 M(-110.4%) | $230.29 M(-0.5%) |
| Jun 2024 | - | $268.62 M(-1079.3%) | $231.54 M(-465.7%) |
| Mar 2024 | - | -$27.43 M(-261.7%) | -$63.32 M(-9.8%) |
| Dec 2023 | -$70.24 M(-35.0%) | $16.96 M(-163.7%) | -$70.24 M(-40.9%) |
| Sep 2023 | - | -$26.61 M(+1.4%) | -$118.83 M(+1.2%) |
| Jun 2023 | - | -$26.24 M(-23.6%) | -$117.42 M(+12.0%) |
| Mar 2023 | - | -$34.35 M(+8.6%) | -$104.82 M(-3.1%) |
| Dec 2022 | -$108.14 M(+0.3%) | -$31.64 M(+25.5%) | -$108.14 M(+4.5%) |
| Sep 2022 | - | -$25.20 M(+84.8%) | -$103.44 M(-3.1%) |
| Jun 2022 | - | -$13.63 M(-63.8%) | -$106.71 M(-8.6%) |
| Mar 2022 | - | -$37.67 M(+39.8%) | -$116.78 M(+8.3%) |
| Dec 2021 | -$107.86 M(+48.8%) | -$26.94 M(-5.4%) | -$107.86 M(+8.1%) |
| Sep 2021 | - | -$28.47 M(+20.1%) | -$99.79 M(+13.9%) |
| Jun 2021 | - | -$23.70 M(-17.6%) | -$87.61 M(+2.6%) |
| Mar 2021 | - | -$28.76 M(+52.4%) | -$85.39 M(+17.8%) |
| Dec 2020 | -$72.48 M(+74.5%) | -$18.87 M(+15.8%) | -$72.48 M(+6.7%) |
| Sep 2020 | - | -$16.29 M(-24.2%) | -$67.91 M(+3.1%) |
| Jun 2020 | - | -$21.48 M(+35.6%) | -$65.86 M(+61.8%) |
| Mar 2020 | - | -$15.85 M(+10.9%) | -$40.71 M(-2.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$41.53 M(-16.9%) | -$14.29 M(+0.3%) | -$41.53 M(+11.1%) |
| Sep 2019 | - | -$14.25 M(-488.2%) | -$37.37 M(+15.3%) |
| Jun 2019 | - | $3.67 M(-122.0%) | -$32.40 M(-37.0%) |
| Mar 2019 | - | -$16.66 M(+64.4%) | -$51.47 M(+3.1%) |
| Dec 2018 | -$49.95 M(-1390.0%) | -$10.13 M(+9.3%) | -$49.95 M(-7.4%) |
| Sep 2018 | - | -$9.28 M(-39.8%) | -$53.96 M(+1255.5%) |
| Jun 2018 | - | -$15.40 M(+1.7%) | -$3.98 M(+337.5%) |
| Mar 2018 | - | -$15.14 M(+7.0%) | -$910.00 K(-123.5%) |
| Dec 2017 | $3.87 M(-112.9%) | -$14.15 M(-134.8%) | $3.87 M(-53.6%) |
| Sep 2017 | - | $40.70 M(-430.2%) | $8.34 M(-121.2%) |
| Jun 2017 | - | -$12.33 M(+19.0%) | -$39.34 M(+12.1%) |
| Mar 2017 | - | -$10.36 M(+7.0%) | -$35.09 M(+17.1%) |
| Dec 2016 | -$29.97 M(+108.4%) | -$9.68 M(+38.7%) | -$29.97 M(+19.7%) |
| Sep 2016 | - | -$6.98 M(-13.5%) | -$25.03 M(+14.7%) |
| Jun 2016 | - | -$8.07 M(+54.1%) | -$21.82 M(+26.9%) |
| Mar 2016 | - | -$5.24 M(+10.6%) | -$17.19 M(+19.5%) |
| Dec 2015 | -$14.38 M(+85.8%) | -$4.74 M(+25.7%) | -$14.38 M(+49.1%) |
| Sep 2015 | - | -$3.77 M(+9.4%) | -$9.65 M(+64.1%) |
| Jun 2015 | - | -$3.44 M(+41.6%) | -$5.88 M(+141.6%) |
| Mar 2015 | - | -$2.43 M | -$2.43 M |
| Dec 2014 | -$7.74 M | - | - |
FAQ
- What is Protagonist Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual CFO year-on-year change?
- What is Protagonist Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly CFO year-on-year change?
- What is Protagonist Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM CFO year-on-year change?
What is Protagonist Therapeutics annual cash flow from operations?
The current annual CFO of PTGX is $184.15 M
What is the all time high annual CFO for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual cash flow from operations is $184.15 M
What is Protagonist Therapeutics annual CFO year-on-year change?
Over the past year, PTGX annual cash flow from operations has changed by +$254.39 M (+362.19%)
What is Protagonist Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PTGX is -$29.18 M
What is the all time high quarterly CFO for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly cash flow from operations is $268.62 M
What is Protagonist Therapeutics quarterly CFO year-on-year change?
Over the past year, PTGX quarterly cash flow from operations has changed by -$1.31 M (-4.72%)
What is Protagonist Therapeutics TTM cash flow from operations?
The current TTM CFO of PTGX is $184.15 M
What is the all time high TTM CFO for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM cash flow from operations is $231.54 M
What is Protagonist Therapeutics TTM CFO year-on-year change?
Over the past year, PTGX TTM cash flow from operations has changed by -$46.14 M (-20.03%)